Targeted Agents Fail to Extend Survival in Pediatric Brainstem Glioma

Diffuse intrinsic pontine glioma remains the most lethal pediatric central nervous system malignancy, characterized by an invasive growth pattern in the brainstem that precludes surgical resection [1, 2]. Standard management relies almost exclusively on palliative radiotherapy, which typically provides only a transient clinical benefit before nearly universal disease progression within six to nine months [3]. Despite more than 50 years of clinical investigation into various cytotoxic and targeted agents, no systemic therapy has successfully extended overall survival beyond the historical baseline [4]. However, the increasing use of stereotactic biopsy has enabled a more sophisticated understanding of the molecular drivers behind these tumors, including specific histone mutations and altered signaling pathways [5]. The BIOMEDE trial evaluated whether this molecular insight could be translated into a biomarker-driven therapeutic strategy, testing targeted agents matched to specific tumor profiles.